PROSTALUND AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.55 SEK | -6.14% |
|
-14.86% | -66.26% |
| May. 31 | ProstaLund Secures Order for CoreTherm System in Austria | MT |
| May. 16 | ProstaLund AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 17.41M 1.65M | Sales 2023 | 22.21M 2.11M | Capitalization | 125M 11.85M |
|---|---|---|---|---|---|
| Net income 2022 | -11M -1.04M | Net income 2023 | -17M -1.61M | EV / Sales 2022 | 12.5 x |
| Net cash position 2022 | 10.54M 1M | Net cash position 2023 | 14.02M 1.33M | EV / Sales 2023 | 4.99 x |
| P/E ratio 2022 |
-19
x | P/E ratio 2023 |
-6.52
x | Employees | 8 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 46.93% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -6.14% | ||
| 1 week | -14.86% | ||
| Current month | -14.86% | ||
| 1 month | -50.89% | ||
| 3 months | -60.00% | ||
| 6 months | -66.57% | ||
| Current year | -66.26% |
1 week
0.53
0.67
1 month
0.481.20
Current year
0.481.90
1 year
0.483.04
3 years
0.486.72
5 years
0.487.94
10 years
0.4825.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 23-09-30 | |
Niclas Nyström
DFI | Director of Finance/CFO | 59 | Dec. 05 |
Johan Laven
SAM | Sales & Marketing | 51 | Dec. 31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul de Potocki
BRD | Director/Board Member | 62 | 23-10-11 |
| Director/Board Member | 59 | 23-04-30 | |
| Director/Board Member | 60 | 23-10-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 0.55 | -6.14% | 33 799 |
| 24-06-05 | 0.586 | -2.01% | 101,431 |
| 24-06-04 | 0.598 | +4.91% | 74,424 |
| 24-06-03 | 0.57 | -11.76% | 83,055 |
| 24-05-31 | 0.646 | +17.88% | 168,285 |
Delayed Quote Nasdaq Stockholm, June 07, 2024 at 11:29 am EDT
More quotes
ProstaLund AB is a Sweden-based company that provides health care products and services. The Company develops and manufactures urological devices and treatments primarily for benign prostatic hyperplasia (BPH). The Company develops CoreTherm, a patented Thermotherapy treatment method for BPH, which takes approximately 6-15 minutes and offers long-term symptom relief. CoreTherm is used in hospitals and clinics in Sweden and worldwide.
Calendar
2024-08-19
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -66.26% | 4.31M | |
| -2.26% | 181B | |
| +2.05% | 108B | |
| -1.31% | 69.41B | |
| +14.65% | 46.61B | |
| -6.69% | 45.85B | |
| +7.97% | 42.61B | |
| +18.60% | 30.71B | |
| +16.92% | 25.63B | |
| -6.87% | 23.32B |
- Stock Market
- Equities
- PLUN Stock
